A December 29th Clinical Leader piece summed up the most influential biosimilar developments of 2016. The list is a compilation of events that were widely covered by the media and are bound to play a major role in how the biosimilar industry unfolds. Below is the list of events, but please visit the article for more details and a list of honorable mentions.
- Conclusion of BsUFA II Negotiations
- CVS, UnitedHealth Choose biosimilars for 2017 Formularies
- The Solicitory General Sides With Sandoz On Patent Dance
- NOR-SWITCH Study Releases Results: Switching Deemed Safe
- Extrapolation Recognized as Key Component of Biosimilarity